clinical trial · NCT06635772
A Study of the Effect and Safety of HS-10390 in the Treatment of Patients with Primary IgA Nephropathy
Hansoh BioMedical R&D Company·phase2·not yet recruiting·n = 90
Immunoglobulin a NephropathyHS-10390Irbesartan
brief summary
This study will evaluate the efficacy and safety of HS-10390 in subjects with primary IgA nephropathy, and explore the optimal dose for the treatment.
started
Nov 1, 2024
primary completion
Dec 1, 2025
completion
Apr 30, 2026
last updated
Oct 10, 2024
official title
A Randomized, Multicenter, Open-label, Active-control Study of the Efficacy and Safety of HS-10390 for the Treatment of Immunoglobulin a Nephropathy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol